Histologic findings of liver injury during pembrolizumab-axitinib treatment
Related Experiment Video
Updated: May 5, 2026
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Rita Carrilho Pichel1, Hugo Miguel Miranda1, Diogo Carvalho Sá2
1Medical Oncology, Centro Hospitalar Universitário de Santo António, Portugal.
Abstract:
Hepatotoxicity is a significant concern in systemic cancer treatments. The pembrolizumab-axitinib combination, used in advanced renal cell carcinoma (RCC), is associated with a 22% incidence of ≥G3 liver enzyme elevations. In this case report we provide the first description of liver biopsy findings of axitinib or pembrolizumab-axitinib drug-induced liver injury (DILI). These findings may enhance understanding of the hepatotoxic effects of this combination and inform strategies for patient management.
More Related Videos
08:15A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth
Published on: February 2, 2024
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
